Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. / Rask, Lene; Balslev, Eva; Søkilde, Rolf; Høgdall, Estrid; Flyger, Henrik; Eriksen, Jens; Litman, Thomas.

I: Cellular oncology (Dordrecht), Bind 37, Nr. 3, 06.2014, s. 215-227.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rask, L, Balslev, E, Søkilde, R, Høgdall, E, Flyger, H, Eriksen, J & Litman, T 2014, 'Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status', Cellular oncology (Dordrecht), bind 37, nr. 3, s. 215-227. https://doi.org/10.1007/s13402-014-0176-6

APA

Rask, L., Balslev, E., Søkilde, R., Høgdall, E., Flyger, H., Eriksen, J., & Litman, T. (2014). Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cellular oncology (Dordrecht), 37(3), 215-227. https://doi.org/10.1007/s13402-014-0176-6

Vancouver

Rask L, Balslev E, Søkilde R, Høgdall E, Flyger H, Eriksen J o.a. Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cellular oncology (Dordrecht). 2014 jun;37(3):215-227. https://doi.org/10.1007/s13402-014-0176-6

Author

Rask, Lene ; Balslev, Eva ; Søkilde, Rolf ; Høgdall, Estrid ; Flyger, Henrik ; Eriksen, Jens ; Litman, Thomas. / Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. I: Cellular oncology (Dordrecht). 2014 ; Bind 37, Nr. 3. s. 215-227.

Bibtex

@article{84fa6911957b436980fb5e5e939d9027,
title = "Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status",
abstract = "PURPOSE: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.METHODS: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.RESULTS: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).CONCLUSION: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.",
keywords = "Faculty of Health and Medical Sciences",
author = "Lene Rask and Eva Balslev and Rolf S{\o}kilde and Estrid H{\o}gdall and Henrik Flyger and Jens Eriksen and Thomas Litman",
year = "2014",
month = "6",
doi = "10.1007/s13402-014-0176-6",
language = "English",
volume = "37",
pages = "215--227",
journal = "Cellular oncology (Dordrecht)",
issn = "2211-3428",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status

AU - Rask, Lene

AU - Balslev, Eva

AU - Søkilde, Rolf

AU - Høgdall, Estrid

AU - Flyger, Henrik

AU - Eriksen, Jens

AU - Litman, Thomas

PY - 2014/6

Y1 - 2014/6

N2 - PURPOSE: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.METHODS: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.RESULTS: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).CONCLUSION: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.

AB - PURPOSE: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.METHODS: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.RESULTS: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).CONCLUSION: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.

KW - Faculty of Health and Medical Sciences

U2 - 10.1007/s13402-014-0176-6

DO - 10.1007/s13402-014-0176-6

M3 - Journal article

VL - 37

SP - 215

EP - 227

JO - Cellular oncology (Dordrecht)

JF - Cellular oncology (Dordrecht)

SN - 2211-3428

IS - 3

ER -

ID: 119643790